An interventional study of blood samples collection in Breast Cancer Female, sponsored by Centre Jean Perrin. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Centre Jean Perrin · Not applicable, Interventional, and Basic science
Among 24 studies in Breast Neoplasms by Centre Jean Perrin — 2 open to participants now, 3 under way, none of them phase 3. Breast Neoplasms · Centre Jean Perrin.
Among the 24 studies in Breast Neoplasms by Centre Jean Perrin, this one is the 4th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2021, is one of 13 with no phase, and was the 19th registered.
14,825 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →2 of the 24 studies in Breast Neoplasms by Centre Jean Perrin are open now, in 1 country. Recruiting first, the newest first:
Centre Jean Perrin · Sites in France
By country, each count listing its studies:
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 85 is above the median of 72 across 10,896 interventional studies indexed under Breast Neoplasms.
Median enrollment 36 across the 21 interventional studies, 240 across the 3 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre Jean Perrin is the lead sponsor of 55 studies on the registry; 8 are open to participants now.
1 of the studies in Breast Neoplasms by Centre Jean Perrin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06512558Centre Jean PerrinAugmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery | 2027-11-01 |
Among the 24 studies in Breast Neoplasms by Centre Jean Perrin, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Major woman with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic analysis will be performed in patients who got a successful PDX
Biological: blood samples collection
Serology and genetic analyses will be performed in patients blood samples
Percentage of successfull PDX
PDX will be realized from patient tumor by transplanting a small fragment in a nude mouse. Once the tumor is enough grown up, the tumor is extracted to repeat this step 3 times until we get the fourth PDX with a successful tumor growth.
Time frame: 2 years
Histological subtype
Comparaison of initial tumor histological subtype with PDX histological subtype
Time frame: 2 years and 4 months
expression of estrogen receptors
Comparaison of initial tumor expression of estrogen receptors with PDX expression of estrogen receptors
Time frame: 2 years and 4 months
expression of progesterone receptors
Comparaison of initial tumor expression of progesterone receptors with PDX expression of progesterone receptors
Time frame: 2 years and 4 months
status of the amplification of the ERBB2 gene
Comparaison of initial tumor's ERBB2 gene amplification status with PDX's ERBB2 gene amplification status
Time frame: 2 years and 4 months
expression of androgen receptors
Comparaison of initial tumor expression of androgen receptors with PDX expression of androgen receptors
Time frame: 2 years and 4 months
tumor molecular classification
Comparaison of initial tumor molecular expression with PDX molecular classification (luminal A, luminal B, HER2 enriched or triple negative)
Time frame: 2 years and 4 months
Exome sequencing
Comparaison of genetic alterations between intial tumor, PDX and blood sample
Time frame: 2 years and 4 months
Plan to share: No
Started Nov 2021 (actual). Primary completion is estimated for Aug 2030, 105 months after the start.
Of 2,661 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 105 months is above that.
Counting every sponsor, half of 2,771 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Jean Perrin